ANI Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $190,574 | $148,332 | $138,040 | $137,430 |
Gross Profit | 190,574 | 85,257 | 65,645 | 73,587 |
EBITDA | 14,853 | -13,419 | 23,725 | 29,741 |
EBIT | -7,747 | -29,167 | 9,028 | 15,055 |
Net Income | -10,276 | -24,166 | -2,287 | 18,207 |
Net Change In Cash | 190,574 | 148,332 | 138,040 | 137,430 |
Free Cash Flow | 13,380 | 7,031 | 12,965 | 13,688 |
Cash | 144,861 | 144,982 | 240,110 | 228,597 |
Basic Shares | 19,445 | 19,404 | 19,321 | 19,422 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $614,376 | $486,816 | $316,385 | $216,136 |
Gross Profit | 614,376 | 305,303 | 177,600 | 115,526 |
EBITDA | 63,121 | 106,599 | 48,068 | -1,684 |
EBIT | -4,610 | 46,808 | -8,904 | -48,936 |
Net Income | -18,522 | 18,779 | -47,896 | -42,603 |
Net Change In Cash | 614,376 | 486,816 | 316,385 | 216,136 |
Cost of Revenue | -52,067 | 92,434 | ||
Free Cash Flow | 64,017 | 100,448 | -47,658 | -20,316 |
Cash | 144,861 | 221,121 | 48,228 | 100,300 |
Basic Shares | 19,318 | 18,194 | 16,260 | 12,596 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.55 |
2024-09-30 | $1.34 |
2024-06-30 | $1.02 |
2024-03-31 | $1.21 |
